CAR-T cell therapy has shown unparalleled success in haematological malignancies, paving the way for the field of immuno-oncology. In 2017 two therapies achieved FDA approval in the USA, and following recent approval by the EMA, it is a landmark time for the industry.
Despite the huge successes there are still a number of hurdles to overcome before CAR-T can be effective in mainstream oncology beyond haematological malignancies. The European CAR-T Congress’ mission is to address the opportunities and challenges that presently face the CAR-T field, to maximise the potential of this ground-breaking therapy.
Hear first-hand the story behind the successes of Novartis & Kite on their roads to approval. Discover how to improve manufacturing with automation to lower cost and increase the scope and reach of the therapies from innovators such as Torque Therapeutics. Explore the viability of allogeneic CAR-T with Cellectis, Celyad and Servier on their approaches to off-the-shelf products. Atillio Bondanza also shares strategies to improve safety with a better understanding of the underlying mechanisms of toxicity.
20+ industry leaders will be offering insight on:
- Solid tumour targeting: overcoming the tumour microenvironment
- Multi-specific & dual targeting CARs
- Process development, scalability & automation
- Allogeneic vs Autologous: the potential of off-the-shelf therapies
- Patient access, implementation & regulatory challenges
- Advances in gene engineering
- Safety and toxicity
There is also a dedicated poster session, whereby attendees can showcase their latest research to the CAR-T community, deadline for submissions 14th December 2018.
Save up to £300 by booking on the early bird rate before Friday 30th November 2018. 2019 is going to be a big year for CAR-T in Europe, don’t be the one to miss out on the latest developments.
To learn more about this event, and to register online, visit www.car-tcongresseu.com